FDA Approved: FULPHILA — Supplemental Application (Biocon Biologics Inc.)

View source ↗

Summary

FDA approved a supplemental application for Fulphila (pegfilgrastim-jmdb) from Biocon Biologics Inc., expanding its regulatory status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Febrile Neutropenia
• Neutropenia

Drugs mentioned

• Fulphila (pegfilgrastim)

Snippet

SUPPL AP for FULPHILA (PEGFILGRASTIM-JMDB)